Lavendustin A

EGFR inhibitor

Cell permeable tyrosine kinase inhibitor with little effect on cAMP-dependent protein kinase (PKA) or protein kinase C (PKC). Potent and selective inhibitor of the EGF receptor tyrosine kinase (IC $_{50}$ =11nM). Binds to a site on the kinase which is distinct from the ATP and peptide substrate binding sites. Inhibits EGF-induced proliferation of cultured human myometrial smooth muscle cells and suppresses VEGF-induced angiogenesis in rats. Effective at 10µM in cultured leech neurons. Also inhibits NMDA-stimulated cGMP production.

Citations: 12

View Online »


Ordering Information

Order Online »

BML-EI185-0001	1mg
BML-El185-0005	5mg

Manuals, SDS & CofA

View Online »



Handling & Storage

Use/Stability As indicated on product label or CoA when stored as recommended. Stable for at least

1 year after receipt when stored, as supplied, at -20°C.

Handling Protect from oxygen.

Long Term Storage -20°C

Shipping Ambient Temperature

Regulatory Status RUO - Research Use Only

Product Details

Alternative Name 5-Amino-[(N-2,5-dihydroxybenzyl)-N'-2-

hydroxybenzyl]salicylic acid, RG14355

Appearance Off-white to tan solid.

CAS 125697-92-9

Couple Target EGFR

Couple Type Inhibitor

Formula $C_{21}H_{19}NO_6$

MW 381.4

Purity ≥95% (HPLC)

Solubility Soluble in DMSO or ethanol.

Last modified: May 29, 2024

